WO2004096207A1 - 体温低下抑制剤 - Google Patents
体温低下抑制剤 Download PDFInfo
- Publication number
- WO2004096207A1 WO2004096207A1 PCT/JP2004/006304 JP2004006304W WO2004096207A1 WO 2004096207 A1 WO2004096207 A1 WO 2004096207A1 JP 2004006304 W JP2004006304 W JP 2004006304W WO 2004096207 A1 WO2004096207 A1 WO 2004096207A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- body temperature
- glycine
- cysteine
- group
- Prior art date
Links
- 230000036760 body temperature Effects 0.000 title claims abstract description 58
- 230000000994 depressogenic effect Effects 0.000 title abstract 5
- 235000001014 amino acid Nutrition 0.000 claims abstract description 88
- 150000001413 amino acids Chemical class 0.000 claims abstract description 88
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 62
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 35
- 230000007423 decrease Effects 0.000 claims abstract description 34
- 239000003792 electrolyte Substances 0.000 claims abstract description 33
- 239000004471 Glycine Substances 0.000 claims abstract description 31
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 31
- 235000003704 aspartic acid Nutrition 0.000 claims abstract description 30
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims abstract description 30
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 30
- 238000001802 infusion Methods 0.000 claims abstract description 29
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000004474 valine Substances 0.000 claims abstract description 27
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 30
- 235000018417 cysteine Nutrition 0.000 claims description 28
- 206010002091 Anaesthesia Diseases 0.000 claims description 24
- 230000037005 anaesthesia Effects 0.000 claims description 24
- 239000003112 inhibitor Substances 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 22
- 230000002631 hypothermal effect Effects 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- JOHZPMXAZQZXHR-UHFFFAOYSA-N pipemidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCNCC1 JOHZPMXAZQZXHR-UHFFFAOYSA-N 0.000 claims description 15
- 238000001990 intravenous administration Methods 0.000 claims description 12
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 11
- 230000009545 invasion Effects 0.000 claims description 9
- 238000001356 surgical procedure Methods 0.000 claims description 9
- 238000011084 recovery Methods 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 3
- 239000011574 phosphorus Substances 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- 230000006433 tumor necrosis factor production Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 102100025036 Norrin Human genes 0.000 claims 1
- 101710085992 Norrin Proteins 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002695 general anesthesia Methods 0.000 abstract description 11
- 229940024606 amino acid Drugs 0.000 description 76
- 239000000243 solution Substances 0.000 description 36
- 239000012153 distilled water Substances 0.000 description 26
- 239000007924 injection Substances 0.000 description 26
- 238000002347 injection Methods 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- 239000011734 sodium Substances 0.000 description 24
- 229960004295 valine Drugs 0.000 description 24
- 150000002500 ions Chemical class 0.000 description 23
- 229960005261 aspartic acid Drugs 0.000 description 21
- 229960002433 cysteine Drugs 0.000 description 21
- 230000003444 anaesthetic effect Effects 0.000 description 15
- 238000001914 filtration Methods 0.000 description 13
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 12
- 229960002449 glycine Drugs 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 6
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 6
- 229960004134 propofol Drugs 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- 239000008151 electrolyte solution Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- -1 inorganic acid salts Chemical class 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229960003067 cystine Drugs 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000003978 infusion fluid Substances 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 229940116871 l-lactate Drugs 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 206010048038 Wound infection Diseases 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 210000004534 cecum Anatomy 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 210000004731 jugular vein Anatomy 0.000 description 3
- 238000002690 local anesthesia Methods 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 2
- WSSSPWUEQFSQQG-UHFFFAOYSA-N 4-methyl-1-pentene Chemical compound CC(C)CC=C WSSSPWUEQFSQQG-UHFFFAOYSA-N 0.000 description 2
- 206010008531 Chills Diseases 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000037007 arousal Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000012774 insulation material Substances 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 238000002350 laparotomy Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 2
- NGSFWBMYFKHRBD-DKWTVANSSA-M sodium;(2s)-2-hydroxypropanoate Chemical compound [Na+].C[C@H](O)C([O-])=O NGSFWBMYFKHRBD-DKWTVANSSA-M 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 241001535291 Analges Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- 125000001176 L-lysyl group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 125000002252 acyl group Chemical class 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000000071 blow moulding Methods 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002692 epidural anesthesia Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000013842 nitrous oxide Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000012603 secondary packaging material Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 229960002078 sevoflurane Drugs 0.000 description 1
- DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical compound FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000002693 spinal anesthesia Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
Definitions
- the present invention relates to, for example, an agent for suppressing hypothermia in the form of a drug or a food, particularly an agent for suppressing hypothermia that suppresses a decrease in body temperature due to general anesthesia during surgery.
- the body temperature regulation mechanism is suppressed by general anesthesia, so that the patient becomes susceptible to the surrounding environmental temperature and the patient's body temperature (core temperature) decreases.
- This decrease in body temperature has led to complications such as chills 'discomfort, shivering, tachycardia', changes in ischemic electrocardiogram, delayed arousal, wound infection, delayed wound healing, reduced immunity, and blood clotting disorders.
- heat insulation materials such as aluminum heat insulation materials, circulation heating mats, heating infusions, and warm air heating during surgery.
- the conventional circulating heating mat has a limited area of heat retention depending on the position of the patient, and the heat retention effect is not sufficient.
- warm air heating is an effective means, but it requires a consumable such as a warming cover that covers the patient, which is a problem in terms of cost. If the decrease in body temperature falls below the threshold of the body temperature center, it takes a long time to recover the body temperature, even if conventional warming measures are taken.
- a high-dose integrated amino acid infusion preparation total amino acid concentration of 1 ow / v% or more was effective in suppressing hypothermia (Eva SeUden, et al: Anesth Analg 89: 1551-1556).
- An object of the present invention is to provide an agent for suppressing hypothermia, which suppresses hypothermia due to general anesthesia and the like, and prevents and / or ameliorates complications associated with hypothermia.
- Another object of the present invention is to provide an agent for suppressing a decrease in body temperature in the form of a pharmaceutical product or a food or drink.
- Another object of the present invention is to provide a hypothermic inhibitor that prevents and / or ameliorates perioperative complications.
- Another object of the present invention is to provide a peripheral blood mononuclear cell TNF-producing inhibitor.
- Another object of the present invention is to provide an infusion for intravenous administration.
- the present inventors have conducted intensive studies on various types of amino acids in order to achieve the above object.As a result, during general anesthesia, lower doses of amino acids than those reported so far have an effect of suppressing a decrease in body temperature. Have found that a certain amino acid alone has an inhibitory effect on body temperature decrease, and have completed the present invention.
- the present invention provides an agent for suppressing hypothermia, comprising as an active ingredient at least one amino acid selected from the group consisting of norin, aspartic acid, criricine and cysteine.
- the present invention also provides a body temperature lowering inhibitor comprising, as an active ingredient, an amino acid mixture comprising at least two kinds of amino acids selected from the group consisting of palin, aspartic acid, glycine and cysteine. .
- the present invention also provides a peripheral blood mononuclear cell TNF production inhibitor comprising at least one amino acid selected from the group consisting of valine, aspartic acid, glycine and cysteine as an active ingredient. I do.
- the present invention also relates to the group consisting of palin, aspartic acid, glycine and cysteine
- An infusion for intravenous administration comprising at least one amino acid selected from the group consisting of: BEST MODE FOR CARRYING OUT THE INVENTION
- Amino acids that can be used as an active ingredient in the agent for suppressing hypothermia of the present invention are valine, aspartic acid, glycine, and cysteine, and valine is more preferable. Each of these amino acids may be contained as a single amino acid, or each amino acid may be contained in any combination. Amino acids used as the active ingredient are preferably valine, aspartic acid, glycine, and cysteine, and preferably do not contain other amino acids. However, if necessary, other amino acids may be used. Each amino acid can be used irrespective of commercial products, synthetic products, and other production methods. Any of the D-form, L-form and DL-form can be used, but the L-form is preferred.
- Each amino acid does not necessarily need to be used as a free amino acid, and may be in the form of a salt acceptable for pharmaceuticals or foods and drinks, for example, inorganic acid salts, organic acid salts, in vivo hydrolysable esters, N- It may be used in the form of an acyl derivative or the like. Further, they may be used in the form of peptides in which the same or different amino acids are peptide-bonded. Cystine may be used in the form of cystine.
- the administration method of the body temperature lowering inhibitor of the present invention can be oral administration, intravenous administration, etc., but is not particularly limited thereto. In the case of intravenous administration, it is preferable to continuously administer it from the peripheral vein, central vein and the like.
- the dosage of palin, aspartic acid, glycine, and cysteine as the active ingredients can be appropriately selected depending on the administration method, patient symptoms and severity, and the type of dosage form.
- 1 Omg per dose for each dose It may be administered within the range of ⁇ 100 mg.
- the dose should be about 1/20 to 1/2 that of oral administration.
- These dosages may be administered in several divided doses if necessary, or may be administered several times a day as needed.
- 1 It is preferable to administer at an administration rate in the range of 0 mg to 100 mg / kg / hr for at least about 2 hours.
- the administration is preferably performed before the body temperature decreases or before the start of anesthesia. It is also preferable to administer continuously or continuously during anesthesia.
- the pharmaceutical form of the hypothermia inhibitor of the present invention for example, a pharmaceutical preparation
- a pharmaceutical preparation can be changed depending on the administration method and is not particularly limited.
- liquids, tablets, capsules, granules, fine granules, powders, powders and the like can be considered.
- suitable pharmaceutically acceptable liquid or solid excipients fillers, extenders, solvents, emulsifiers, lubricants, flavor correctors, flavors, dyes, It is preferable to add an auxiliary agent such as a buffer substance.
- the body temperature decrease inhibitor of the present invention is preferably in the form of an infusion preparation, the embodiment of the infusion preparation will be particularly described in detail.
- the infusion preparation may contain any of valine, aspartic acid, glycine and cysteine or any combination of valine, aspartic acid, glycine and cysteine. Also, it is not necessary to contain amino acids other than valine, aspartic acid, glycine and cysteine, and it is more preferable not to contain other amino acids in consideration of the possibility of affecting the effect of the active ingredient amino acid. Yes.
- At least one amino acid of norin, aspartic acid, glycine, and cysteine is 10% or less, preferably 0.01 to 9 W / V%.
- the concentration may be set in the range of 0.03 to 6 W / V%, more preferably 0.05 to 4 W / V%, and most preferably 0.1 to 3.3%.
- the total amino acid concentration is preferably less than 10 W / V%, more preferably in the range of 1 to 9 W / V%. , Most preferably 1.5-5W / V% Range.
- the total amino acid concentration is less than 10 W / V%, preferably 1 to 9 W / V%, more preferably 1.5 to 5 W / V%.
- An amino acid preparation may be used.
- L-threonine 0.05 0.8 (preferably 0.1 to 0.4) WZV% L-tryptophan 0.01 1.0 (preferably 0.02 to 0.5) WZV% L-valine 0.01 '2.0 (preferably 0.05 to 1.0) WZV% L-alanine 0.051.0 (Preferably 0.1 to 0.5) W / V% L-arginine 0.051.0 (preferably 0.1 to 0.5) W / V% L-aspartic acid 0.011.0 (preferably 0.02 to 0.5) WZV% L-cysteine 0.005 to 0.5 (Preferably 0.01 to 0.1) W / V% L-glucamic acid 0.005 to 0.5 (preferably 0.01 0.25) WZV% L-histidine 0.01 to 0.5 (preferably 0.05 to 0.3) WV% L-proline 0.01 to: L 0.0 (preferably 0.05 to 0.5) W / V% L-serine 0.01 to 1.0 (preferably 0.02 to 0.5) W / V% L-tyros
- the above-mentioned infusion preparation may be arbitrarily blended with a required amount of components such as an electrolyte, a sugar, a pH adjuster, a trace element, and a vitamin which are usually used as an infusion component. In particular, it is preferable to incorporate an electrolyte.
- the electrolyte referred to here is a compound that generates ions in an aqueous solution, and particularly, an inorganic salt or an organic salt that generates ions such as Na +, K +, and C ⁇ ⁇ in an aqueous solution is preferable. More specifically, it is preferable that an electrolyte which generates ions in the following concentration ranges is blended.
- electrolytes that generate Na + include sodium chloride, sodium L-lactate, sodium catenate, sodium bicarbonate, sodium dihydrogen phosphate, sodium monohydrogen phosphate, and sodium acetate.
- the electrolyte that generates K + includes potassium chloride.
- Cri5.0 Examples of electrolytes that generate 0 to 16 OmEq / L include sodium chloride, potassium chloride, calcium chloride, and magnesium chloride.
- pH of such an infusion preparation is adjusted to 3.0 to 8.5. More convenient infusion preparations include palin, aspartic acid,
- Cystine may be directly incorporated into an existing infusion preparation, in which case the hypothermia inhibitor of the present invention may be used in the form of powders, granules, tablets, concentrated liquids, or a combination thereof containing a required amount. May be used.
- an electrolyte solution is preferable, and particularly, an isotonic electrolyte infusion solution and a hypotonic electrolyte infusion solution used in the perioperative period are preferable.
- physiological saline, Ringer's solution, lactate Ringer's solution, Ringer's acetate solution, start Liquid, dehydration replenisher, maintenance liquid, and postoperative recovery liquid are preferred.
- an infusion solution containing sugar in them may be used.
- the above infusion preparation should be used 2 hours before surgery 0.1-6 O ml / kg / hr during the operation ⁇ preferably 10-40 m 1 kg
- the infusion preparation of the body temperature lowering inhibitor of the present invention is preferably filled in a container, and each component may be divided into a plurality of chambers and filled as needed.
- a reducing sugar is added as the saccharide
- the amino acid and the saccharide may preferably be separated and housed since the amino acid and the reducing sugar may cause a Maillard reaction with time.
- the first chamber may be filled with a sugar-electrolyte solution
- the second chamber may be filled with an amino acid solution.
- a method of partitioning into two chambers a method of partitioning with a seal portion that can be peeled off by external pressure during use is preferable.
- a soft resin material which is excellent in flexibility and transparency and hardly breaks even when dropped after storage at low temperature is preferable.
- polyolefins which are usually used for medical containers can be suitably mentioned.
- the polyolefins include polymerization polymers such as polyethylene, polypropylene, poly 1-butene, and poly 4-methyl-pentene.
- the container body may be any of the above-mentioned resins obtained by blow molding, inflation or deflation molding. Alternatively, a resin sheet formed by welding the peripheral edges of two resin sheets may be used.
- a form to be mixed with an existing infusion preparation it may be a container which can contain only the necessary components in a required amount, such as powders, granules, tablets, concentrated solutions, or a combination thereof, or may be a vial.
- a kit product with an existing infusion solution may be used.
- a bicarbonate ion-containing infusion preparation it is preferable to manufacture it by the method described in Japanese Patent No. 3271650, which is filled in a gas-impermeable container or filled in a gas-permeable plastic container. Further, it is preferable to package with a gas impermeable secondary packaging material.
- the body temperature lowering inhibitor of the present invention can be used not only in the form of pharmaceuticals as described above, but also by incorporating it into foods and beverages by referring to the embodiments of the pharmaceuticals, thereby improving its use in foods and beverages. Can be easily implemented.
- the agent for suppressing a decrease in body temperature of the present invention can be used for any symptom (1) of a disease state for the purpose of suppressing a decrease in body temperature, but is particularly useful for suppressing a decrease in body temperature due to anesthesia.
- Anesthesia includes general anesthesia and local anesthesia.
- General anesthesia includes inhalation anesthesia using isoflurane, sevoflurane, analgesic, sedative, and sleeping gas (such as laughing gas), and intravenous anesthesia using provophor.
- the agent for suppressing a decrease in body temperature of the present invention is useful for suppressing the decrease in body temperature due to general anesthesia during surgical operation among these anesthesias.
- At least one amino acid selected from the group consisting of valine, aspartic acid, glycine and cysteine can be used in a dose range in which the effect of the present invention is exerted without reducing the effect of an intravenous anesthetic (propofol). General anesthesia can be introduced.
- At least one amino acid selected from the group consisting of valine, aspartic acid, glycine and cysteine is a perioperative complication that develops during and after surgery (chills, discomfort, shivering, tachycardia, ischemic electrocardiogram) Changes, delayed arousal, perioperative complications such as wound infection, delayed wound healing, decreased immunity, blood clotting disorders, etc., and is also useful for promoting or improving recovery from surgical invasion It is.
- An agent for preventing and / or treating perioperative complications which comprises at least one amino acid selected from the group consisting of parin, aspartic acid, glycine and cysteine of the present invention as an active ingredient, and surgical invasion
- All of the forms of the recovery promoter, the peripheral blood mononuclear cell TNF-suppressor of production decrease, and the infusion for intravenous administration can be prepared in the same manner as the form of the above-mentioned suppressor of body temperature decrease.
- a hypothermia inhibitor that suppresses a decrease in body temperature due to general anesthesia and the like, and prevents and / or ameliorates complications associated with hypothermia, and further provides a hypothermia inhibitor that promotes recovery from surgical invasion.
- the body temperature lowering inhibitor of the present invention the body temperature (core temperature) can be suppressed by adding a caloric solution to the infusion of the cell envelope composition that has been administered in the perioperative period so far, thereby achieving the conventional body temperature. Compared with the method of suppressing the decrease, it can be performed simply and inexpensively. Further, by combining with the conventional method, it is possible to more effectively suppress the decrease in body temperature.
- the phosphoric acid solution, a.spartic acid solution, glycine solution, and cysteine solution are mixed with distilled water for injection so that the respective amino acids become 0.1 W / V%, 1 W / V%, or 2 W / V%.
- the amino acid mixture was prepared by dissolving the amino acids in the amounts shown in Table 1 in distilled water for injection. Each solution was sterilized by filtration before administration.
- the rats used for the evaluation were recovered for several days with a catheter inserted into the external vein beforehand, the tip of which was put out on the back, and locked with heparin.
- Physiological saline solution and 0.1 W / V%, 1.ow / v% palin solution, aspartic acid solution, glycine solution, cysteine solution, and 10.5 ml / kg of the amino acid mixture shown in Table 1 from the insertion catheter Four doses were administered at 15-minute intervals from 60 minutes before administration of the anesthetic (Provophor), followed by continuous administration at 42 m1 / kg for 1 hour at the same time as the start of anesthetic administration. The number of cases in each group was 4 to 6.
- Anesthesia was first administered by intravenous administration of 15 mg / kg bolus via a catheter via a bolus, and continuous administration of 45 mg / kg Zhr was also started at the same time. One hour later, the administration rate was 22.5 mg / kg / hr, and continuous administration was performed for a total of 3 hours.
- the body temperature was measured using a rectal thermometer before administration of the amino acid solution, and at 30-minute intervals from the start of administration of the anesthetic to 3 hours after the end of administration.
- the measurement results were expressed as a standard deviation (average standard deviation) as a change amount (pre-administration value-post-administration value) to each pre-administration value 3 hours after administration of the anesthetic solution.
- the statistical test is to compare the two groups with saline.
- Table 2 shows the results. An inhibitory effect on the decrease in body temperature (core temperature) was observed with a phosphorus solution, an aspartic acid solution, a cysteine solution, a glycine solution, and an amino acid mixture solution.
- Raw food physiological saline solution
- AA amino acid solution
- the administration was carried out from the catheter by the following four methods. In group A, 105 mg / kg (1% valine solution, 10.5 mL / kg) 8 times at 15 minute intervals, and for group B, 105 mg / kg (1% valine solution, 10.5 mL / kg) at 15 minute intervals After 4 doses, then continue to administer 420 mg / kg / hr (1% valine solution at 42 mL kg) for 1 hour, and for groups C and D, administer 420 mg / kg hr (1% valine solution at 42 mL / kg) for 2 hours did.
- Provophor anesthetic was initially administered at 15 mg / kg from the catheter, and after induction anesthesia, was continuously administered at 33.75 mg / kg / hr for 3 hours.
- the decrease in body temperature from before administration to the end of anesthesia was 6.1 ⁇ 1.9 ° C in Group A; 4.3 ⁇ 1.2 ° C in Group B; 6.1 ⁇ 1.4 ° C in Group C; and 6.9 ⁇ 1.0 in Group D.
- the decrease in body temperature in Group B was the smallest, followed by Groups A and C, and the effect of suppressing body temperature decrease was not observed in Group D.
- Body temperature rise from the end of anesthesia administration to 1 hour after the end of anesthesia administration was highest in Group B (2.0 ⁇ 1.2 ° C) and Group C (2.0 ⁇ 0.9 ° C), followed by Group A.
- valine was shown to be effective in producing hypothermia before or at the same time as the administration of propofol anesthetic, and the rise in body temperature after the end of anesthetic administration was observed before or after anesthetic administration. This was strongly observed when palin was administered simultaneously with the administration of an anesthetic. As described above, it is preferable to administer parin before administration of the anesthetic and during administration of the anesthetic.
- valine 105 mg / kg (5.25 ml / kg of 2 W / V% phosphoric acid) was administered 4 times at 15-minute intervals from 60 minutes before administration of the provophor anesthetic via the insertion catheter, and then 42 Omg / kg / hr ( Solution was continuously administered at 21 ml / kg) for 5 hours.
- ⁇ Physiological saline was administered instead of the phosphate solution.
- the administration of propofol anesthesia was started by intravenously administering 15 mg / kg by bolus via the catheter, and immediately after that, continuous administration of 45 mg / kg / hr was started. One hour later, the administration rate was 33.75 mg / kg / hr, and continuous administration was performed for 5 hours. The number of cases in each group was eight.
- the rod was opened, the cecum was exposed from the abdominal cavity, and exposed to air for 30 minutes. After completion of the operation, the cecum was returned to the abdominal cavity and sutured.
- the body temperature was measured with a rectal thermometer before the amino acid administration and 3 hours after the administration of propofol. The results are shown at a reduced temperature relative to the Pre value.
- the survival rate was determined from the number of survivors 24 hours after the start of the experiment.
- the survival rate (one day later) was 12.5% in the control group and 87.5% in the valine group, indicating that the valine administration improved the survival rate.
- the test was performed in three groups: a normal group, a palin administration group, and a control group.
- the rats used for the evaluation (7 to 8 weeks of age) were allowed to recover for several days with a catheter inserted into the external jugular vein in advance, with the tip of the dorsal vertebrae locked with heparin.
- the administration of propofol anesthesia was initially performed at 15 mg / kg via a catheter, followed by induction anesthesia, followed by continuous administration at 33.75 mg / kg / hr for 3 hours.
- PBMC peripheral blood mononuclear cells
- LPS lipopolisa ccaraide
- the values were almost the same as those in the normal group.
- the body temperature at the end of anesthesia administration was 31.2 ⁇ 0.8 ° C in the palin administration group!
- the temperature of the control group was 30.0 ⁇ 1.1 ° C., and the palin administration group showed a higher value than the control group.
- Table 1 1 the amount of amino acids was prepared by dissolving in distilled water for injection, pH of this when filter-sterilized c was 5 ⁇ 71.
- Table 1 2 of the amount of amino acids was prepared by dissolving in distilled water for injection, pH of this when filter-sterilized c was found to be 5.92. Table 1 2
- Example 15 Amino acids and electrolytes having the compounding amounts shown in Table 16 were prepared by dissolving them in distilled water for injection, and sterilized by filtration. At this time, the concentration of each ion was Na +: 154 mEq / L, CI ": 154 mEq / L, and the pH was 5.80. Table 16
- Example 16 Amino acids and electrolytes having the compounding amounts shown in Table 17 were prepared by dissolving in distilled water for injection, and sterilized by filtration. At this time, the concentration of each ion was Na + : 154 mEq / L, CI ": 151 ⁇ 2Eq / L, and the pH was 5.56. Table 17
- Amino acids and electrolytes in the blending amounts shown in Table 18 were prepared by dissolving in distilled water for injection, and sterilized by filtration. At this time, the concentration of each ion was Na + : 35 mEq / L, K + : 20 mEq / L, CI ': 35 mEq / Ls L-Lactate ": 20 mEq / L, and the pH was 5.34.
- Amino acids and electrolytes in the amounts shown in Table 19 were prepared by dissolving in distilled water for injection, and sterilized by filtration. At this time, the concentration of each ion was Na +: 35 mEq / L, K +: 20 mEq / L, CI ": 35 mEq / L, L-Lactate”: 20 mEq / L, and the pH was 5.41.
- the prepared sugar electrolyte solution and amino acid solution are aseptically filtered, and 34 Qml of the sugar electrolyte solution is filled into the first chamber of a plastic container (double bag) separated by a partition wall. After sealing the first chamber, fill the second chamber of each plastic container with 660 ml of amino acid solution and seal it.
- the sealed plastic container filled with both liquids is subjected to high-pressure steam sterilization, and after cooling, it is packed in an outer packaging together with an oxygen scavenger.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005505950A JP5271480B2 (ja) | 2003-04-30 | 2004-04-30 | 体温低下抑制剤 |
EP04730698A EP1618878A1 (en) | 2003-04-30 | 2004-04-30 | Body-temperature lowering depressant |
US11/261,702 US20060063839A1 (en) | 2003-04-30 | 2005-10-31 | Inhibitors of decrease in body temperature |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-125688 | 2003-04-30 | ||
JP2003125688 | 2003-04-30 | ||
JP2003-328588 | 2003-09-19 | ||
JP2003328588 | 2003-09-19 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/261,702 Continuation US20060063839A1 (en) | 2003-04-30 | 2005-10-31 | Inhibitors of decrease in body temperature |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004096207A1 true WO2004096207A1 (ja) | 2004-11-11 |
Family
ID=33422081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/006304 WO2004096207A1 (ja) | 2003-04-30 | 2004-04-30 | 体温低下抑制剤 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20060063839A1 (ja) |
EP (1) | EP1618878A1 (ja) |
JP (1) | JP5271480B2 (ja) |
WO (1) | WO2004096207A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008133157A1 (ja) * | 2007-04-20 | 2008-11-06 | Ajinomoto Co., Inc. | 体温低下抑制剤 |
JP2011241149A (ja) * | 2010-05-14 | 2011-12-01 | Terumo Corp | 消化態経口栄養剤 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1803458A1 (en) * | 2005-12-23 | 2007-07-04 | Scott Cordray | Use of inorganic salts in the treatment of inflammation |
MX2012013932A (es) * | 2010-06-03 | 2013-01-24 | Stokely Van Camp Inc | Mezclas de electrolitos que proporcionan sabor salado reducido. |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03500775A (ja) * | 1987-10-29 | 1991-02-21 | アクチエボラゲット、エリック、ビナルス | 非経口栄養サポート用アミノ酸組成物 |
JPH08502039A (ja) * | 1992-07-17 | 1996-03-05 | ブリガム・アンド・ウイメンズ・ホスピタル | 筋肉の劣化を減少させるための組成物および方法 |
JPH11302164A (ja) * | 1998-04-20 | 1999-11-02 | Shimizu Pharmaceutical Co Ltd | アミノ酸組成物 |
JP2001508648A (ja) * | 1996-11-06 | 2001-07-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 腫瘍壊死因子レセプター放出酵素、酵素を含む組成物、およびその使用方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5310768A (en) * | 1987-10-29 | 1994-05-10 | Ab Erik Vinnars | Method for improving the glutamine content in skeletal muscle and composition therefore |
TW497165B (en) * | 1999-06-30 | 2002-08-01 | Hitachi Ltd | Method for manufacturing semiconductor integrated circuit device, optical mask used therefor, method for manufacturing the same, and mask blanks used therefor |
JP4245746B2 (ja) * | 1999-09-20 | 2009-04-02 | 協和発酵バイオ株式会社 | 発酵法によるアミノ酸の製造法 |
WO2003011056A1 (fr) * | 2001-07-31 | 2003-02-13 | Ajinomoto Co., Inc. | Compositions alimentaires ergogeniques |
-
2004
- 2004-04-30 WO PCT/JP2004/006304 patent/WO2004096207A1/ja active Application Filing
- 2004-04-30 EP EP04730698A patent/EP1618878A1/en not_active Withdrawn
- 2004-04-30 JP JP2005505950A patent/JP5271480B2/ja not_active Expired - Fee Related
-
2005
- 2005-10-31 US US11/261,702 patent/US20060063839A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03500775A (ja) * | 1987-10-29 | 1991-02-21 | アクチエボラゲット、エリック、ビナルス | 非経口栄養サポート用アミノ酸組成物 |
JPH08502039A (ja) * | 1992-07-17 | 1996-03-05 | ブリガム・アンド・ウイメンズ・ホスピタル | 筋肉の劣化を減少させるための組成物および方法 |
JP2001508648A (ja) * | 1996-11-06 | 2001-07-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 腫瘍壊死因子レセプター放出酵素、酵素を含む組成物、およびその使用方法 |
JPH11302164A (ja) * | 1998-04-20 | 1999-11-02 | Shimizu Pharmaceutical Co Ltd | アミノ酸組成物 |
Non-Patent Citations (4)
Title |
---|
SELLDEN E. ET AL: "Amino Acid-Induced Thermogenesis Reduces Hypothermia During Anesthesia and Shortens Hospital Stay", ANESTHESIA & ANALGESIA, vol. 89, no. 6, 1999, pages 1551 - 1556, XP002980820 * |
SELLDEN E. ET AL: "Preoperative infusion of amino acids prevents postoperative hypothermia", BRITISH JOURNAL OF ANAESTHESIA, vol. 96, 1996, pages 227 - 234, XP002980819 * |
SINGH J. ET AL: "Effect of Aspartate and Glutamate on Nociception, Catalepsy and Core Temperature in Rats", INDIAN JOURNAL OF PHYSIOLOGY PHARMACOLOGY, vol. 41, no. 2, 1997, pages 123 - 128, XP002980822 * |
TSUJIKAWA T. ET AL: "Modulation of Thermogenic Response to Parental Amino Acid Infusion in Surgical Stress", NUTRITION, vol. 12, no. 1, 1996, pages 36 - 39, XP002980821 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008133157A1 (ja) * | 2007-04-20 | 2008-11-06 | Ajinomoto Co., Inc. | 体温低下抑制剤 |
US8597691B2 (en) | 2007-04-20 | 2013-12-03 | Ajinomoto Co., Inc. | Anti-hypothermia composition |
JP5482999B2 (ja) * | 2007-04-20 | 2014-05-07 | 味の素株式会社 | 体温低下抑制剤 |
KR101434329B1 (ko) * | 2007-04-20 | 2014-08-27 | 아지노모토 가부시키가이샤 | 체온 저하 억제제 |
JP2011241149A (ja) * | 2010-05-14 | 2011-12-01 | Terumo Corp | 消化態経口栄養剤 |
Also Published As
Publication number | Publication date |
---|---|
US20060063839A1 (en) | 2006-03-23 |
JP5271480B2 (ja) | 2013-08-21 |
JPWO2004096207A1 (ja) | 2006-07-13 |
EP1618878A1 (en) | 2006-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2608483T3 (es) | Método mejorado de administración de beta-hidroxi-beta-metilbutirato (HMB) | |
JP6353577B2 (ja) | 組み合わせ組成物 | |
JP5177785B2 (ja) | 周術期患者用薬剤 | |
CA2568180C (en) | Medical solution, method for producing and use thereof | |
US20150320712A1 (en) | Nutritional Composition for Gastrostomy-Tube Patients | |
JP2007137836A (ja) | 末梢静脈栄養輸液 | |
WO2002100193A1 (en) | Body temperature-raising agent of amino acids for eating or drinking and for medical use | |
JP5552763B2 (ja) | 末梢静脈投与用輸液製剤 | |
JP3937423B2 (ja) | アミノ酸含有アルブミン製剤 | |
WO2004096207A1 (ja) | 体温低下抑制剤 | |
WO2009081991A1 (ja) | 脳虚血障害治療剤 | |
JP2005132831A (ja) | 末梢静脈投与用輸液 | |
JP5769354B2 (ja) | 中心静脈投与用輸液 | |
JP4423682B2 (ja) | 輸液用グルタミン凍結乾燥物の調製法 | |
JP2003160501A (ja) | 微量金属を含む輸液製剤 | |
KR20070116087A (ko) | 고혈압 치료용 약제의 제조를 위한 염산의 이용 | |
JP5603605B2 (ja) | 鉄を含有しない微量元素配合輸液製剤 | |
JP5607408B2 (ja) | アレンドロン酸含有注射剤 | |
JP4178563B2 (ja) | 2室容器入りビタミンb1配合栄養輸液剤 | |
JP6014861B2 (ja) | 末梢静脈投与用輸液製剤 | |
JP2006104077A (ja) | 末梢静脈栄養輸液製剤 | |
JP2005330244A (ja) | 末梢静脈投与用輸液 | |
JP5980529B2 (ja) | 中心静脈投与用輸液製剤 | |
JP2005220105A (ja) | 末梢静脈栄養輸液製剤 | |
JPH0531151A (ja) | 輸液入り容器 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005505950 Country of ref document: JP Ref document number: 11261702 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004730698 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004730698 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11261702 Country of ref document: US |